|
See related Emend Tri-Pack cap information |
|
|
|
Manufacturer |
MSD |
|
Distributor |
Hong Kong: DKSH |
|
Contents |
Aprepitant |
|
Indications |
Prevention of acute & delayed nausea & vomiting associated w/ initial & repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin & moderately emetogenic cancer chemotherapy. |
|
Dosage |
125 mg orally 1 hr prior to chemotherapy (day 1) & 80 mg once daily in the morning on days 2 & 3. Emend is given as part of 3-day regimen that includes a corticosteroid & a 5-HT3 antagonist. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Hypersensitivity. Concurrent administration w/ pimozide, terfenadine, astemizole or cisapride. |
|
Special Precautions |
Patients receiving concomitant medications that are primarily metabolized through CYP3A4. Closely monitor INR in patients on chronic warfarin therapy. May reduce efficacy of OCs. Pregnancy & lactation. |
|
Adverse Drug Reactions |
Hiccups, asthenia/fatigue, increased ALT, constipation, headache, anorexia.
View ADR Monitoring Form |
|
Drug Interactions |
Avoid concurrent administration w/ pimozide, terfenadine, astemizole or cisapride. May lower plasma conc of concomitantly administered S(-) warfarin, tolbutamide or phenytoin. The usual dose of dexamethasone & methylprednisolone should be reduced. Caution & close monitoring when co-administered w/ chemotherapeutic agents (etoposide, vinorelbine, docetaxel & paclitaxel). May increase plasma conc of concomitantly administered midazolam, alprazolam, triazolam. Concomitant administration w/ strong CYP3A4 inhibitors (eg ketoconazole) or CYP3A4 inducers (eg rifampin).
View more drug interactions with Emend Tri-Pack |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
ATC Classification |
A04AD12 - aprepitant ; Belongs to the class of other antiemetics. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Emend Tri-Pack capsule |
|
|
|
Manufacturer: |
MSD |
|
Distributor: |
Hong Kong: DKSH |
|
 |
 |
|
|
